Abstract
Cell targeting and adhesion is an important process yet a great challenging in cell‐based therapies. Here, we demonstrate a DNA aptamer‐based approach to control cell targeting and cell‐cell adhesion with high selectivity and efficiency, which is applied in a immune cell‐killing model. We previously showed that DNA aptamers that generated from cell‐SELEX (Systematic Evolution of Ligands by EXponential enrichment) strategy exhibit high affinity and excellent selectivity toward their target cells. An aptamer‐lipid probe is designed to modify cell surfaces with cell‐targeting aptamers in a rapid and nontoxic way. Modified cells can attach to target cells by aptamer recognition process, which mimics native cell‐surface ligand‐receptor interactions. The selectivity and efficiency of cell targeting is monitored and compared in several physiological relevant conditions. As a prove‐of‐concept study, immune cell‐killing assays are constructed. Natural killer cells and T cells modified with cancer cell‐targeting aptamers demonstrate improved cancer cell targeting and killing.This work is supported by NIH.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
